SG10201605152SA - Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors - Google Patents
Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitorsInfo
- Publication number
- SG10201605152SA SG10201605152SA SG10201605152SA SG10201605152SA SG10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- acid derivatives
- boronic acid
- amino boronic
- immunoproteasome inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579076P | 2011-12-22 | 2011-12-22 | |
| EP11195107 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605152SA true SG10201605152SA (en) | 2016-08-30 |
Family
ID=48667763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605152SA SG10201605152SA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| SG11201403254QA SG11201403254QA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403254QA SG11201403254QA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9688702B2 (es) |
| EP (1) | EP2793900B1 (es) |
| JP (1) | JP6129203B2 (es) |
| KR (1) | KR20140114391A (es) |
| CN (1) | CN104321060B (es) |
| AU (1) | AU2012356890B2 (es) |
| BR (1) | BR112014015363A2 (es) |
| CA (1) | CA2860142C (es) |
| EA (1) | EA201400735A1 (es) |
| ES (1) | ES2699267T3 (es) |
| HK (1) | HK1206261A1 (es) |
| IL (1) | IL233200A (es) |
| MX (1) | MX352652B (es) |
| SG (2) | SG10201605152SA (es) |
| WO (1) | WO2013092979A1 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102205755B1 (ko) | 2010-08-10 | 2021-01-22 | 렘펙스 파머수티클스 인코퍼레이티드 | 고리형 보론산 에스터 유도체의 결정 형태 |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| MX2015006715A (es) | 2012-12-03 | 2015-08-14 | Hoffmann La Roche | Compuestos de acido triazolboronico sustituido. |
| PT2928898T (pt) | 2012-12-07 | 2021-07-05 | Venatorx Pharmaceuticals Inc | Inibidores de beta-lactamase |
| CN104994844A (zh) * | 2013-01-04 | 2015-10-21 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| BR112015016002A2 (pt) * | 2013-01-04 | 2017-07-11 | Rempex Pharmaceuticals Inc | compostos, composições farmacêuticas, complexos químicos e respectivos usos e método para tratar ou prevenir infecção bacteriana |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9403850B2 (en) | 2013-01-10 | 2016-08-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP2970340B1 (en) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9988421B2 (en) | 2014-01-10 | 2018-06-05 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
| PT3140310T (pt) | 2014-05-05 | 2019-11-18 | Rempex Pharmaceuticals Inc | Síntese de sais de boronato e utilizações dos mesmos |
| EP3139930A4 (en) | 2014-05-05 | 2018-01-17 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| KR20170007448A (ko) | 2014-05-19 | 2017-01-18 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| CN109988186A (zh) | 2014-06-11 | 2019-07-09 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| CA2952968A1 (en) * | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN107073069B (zh) | 2014-08-18 | 2022-03-08 | 康奈尔大学 | 作为人免疫蛋白酶体的抑制剂的二肽模拟物 |
| JP6896618B2 (ja) | 2014-10-01 | 2021-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ボロン酸誘導体 |
| ES2761774T3 (es) * | 2014-10-01 | 2020-05-21 | Merck Patent Gmbh | Derivados del ácido borónico |
| ES2811273T3 (es) * | 2014-10-01 | 2021-03-11 | Merck Patent Gmbh | Derivados del ácido borónico |
| JP6835711B2 (ja) * | 2014-10-01 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ボロン酸誘導体 |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP4006012A1 (en) | 2015-10-15 | 2022-06-01 | Cornell University | Proteasome inhibitors and uses thereof |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN107151255A (zh) * | 2016-03-06 | 2017-09-12 | 复旦大学 | 硼酸类化合物及其制备方法和用途 |
| WO2018005662A1 (en) | 2016-06-30 | 2018-01-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2018218190A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| JP7189203B2 (ja) | 2017-08-24 | 2022-12-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ボロン酸誘導体 |
| CN111212843A (zh) | 2017-10-11 | 2020-05-29 | Qpex生物制药有限公司 | 硼酸衍生物及其合成 |
| EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
| CN107556336A (zh) * | 2017-10-16 | 2018-01-09 | 康化（上海）新药研发有限公司 | 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法 |
| WO2019099582A1 (en) | 2017-11-16 | 2019-05-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| CN108130370B (zh) * | 2018-01-05 | 2020-11-17 | 武汉惠康达科技有限公司 | Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用 |
| MX2021000214A (es) | 2018-07-26 | 2021-03-31 | Merck Patent Gmbh | Derivados de acido boronico. |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN114075227B (zh) * | 2020-08-19 | 2023-07-04 | 北京嵩润医药科技有限责任公司 | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 |
| EP4377324A1 (en) | 2021-07-29 | 2024-06-05 | Merck Patent GmbH | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| WO2023061445A1 (zh) * | 2021-10-14 | 2023-04-20 | 首药控股(北京)股份有限公司 | 硼酸衍生物 |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| US7332343B2 (en) * | 2004-01-16 | 2008-02-19 | Board Of Regents, The University Of Texas System | Determining enantiomeric excess using indicator-displacement assays |
| CA2738706C (en) | 2004-03-30 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
| US7855206B2 (en) | 2006-11-14 | 2010-12-21 | Merck Sharp & Dohme Corp. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP2527347A1 (en) * | 2007-08-06 | 2012-11-28 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| WO2009051581A1 (en) | 2007-10-16 | 2009-04-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| EP2220096A1 (en) * | 2007-11-13 | 2010-08-25 | Protez Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| EP2552216B1 (en) * | 2010-03-31 | 2018-01-24 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| EP2563126B1 (en) | 2010-04-30 | 2016-05-11 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
-
2012
- 2012-12-21 JP JP2014548061A patent/JP6129203B2/ja active Active
- 2012-12-21 EP EP12806491.2A patent/EP2793900B1/en active Active
- 2012-12-21 CN CN201280063440.0A patent/CN104321060B/zh active Active
- 2012-12-21 KR KR1020147020413A patent/KR20140114391A/ko not_active Application Discontinuation
- 2012-12-21 MX MX2014007362A patent/MX352652B/es active IP Right Grant
- 2012-12-21 SG SG10201605152SA patent/SG10201605152SA/en unknown
- 2012-12-21 BR BR112014015363A patent/BR112014015363A2/pt not_active Application Discontinuation
- 2012-12-21 AU AU2012356890A patent/AU2012356890B2/en active Active
- 2012-12-21 SG SG11201403254QA patent/SG11201403254QA/en unknown
- 2012-12-21 CA CA2860142A patent/CA2860142C/en active Active
- 2012-12-21 US US14/366,949 patent/US9688702B2/en active Active
- 2012-12-21 ES ES12806491T patent/ES2699267T3/es active Active
- 2012-12-21 WO PCT/EP2012/076595 patent/WO2013092979A1/en active Application Filing
- 2012-12-21 EA EA201400735A patent/EA201400735A1/ru unknown
-
2014
- 2014-06-17 IL IL233200A patent/IL233200A/en active IP Right Grant
-
2015
- 2015-07-21 HK HK15106906.3A patent/HK1206261A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL233200A (en) | 2017-08-31 |
| BR112014015363A8 (pt) | 2017-06-13 |
| CA2860142A1 (en) | 2013-06-27 |
| MX352652B (es) | 2017-12-04 |
| AU2012356890A1 (en) | 2014-08-07 |
| EP2793900A1 (en) | 2014-10-29 |
| EP2793900B1 (en) | 2018-08-22 |
| HK1206261A1 (en) | 2016-01-08 |
| SG11201403254QA (en) | 2014-07-30 |
| WO2013092979A1 (en) | 2013-06-27 |
| CN104321060A (zh) | 2015-01-28 |
| BR112014015363A2 (pt) | 2017-06-13 |
| AU2012356890B2 (en) | 2017-06-08 |
| KR20140114391A (ko) | 2014-09-26 |
| ES2699267T3 (es) | 2019-02-08 |
| JP2015502387A (ja) | 2015-01-22 |
| IL233200A0 (en) | 2014-07-31 |
| CA2860142C (en) | 2020-10-27 |
| EA201400735A1 (ru) | 2015-04-30 |
| US9688702B2 (en) | 2017-06-27 |
| MX2014007362A (es) | 2014-08-01 |
| JP6129203B2 (ja) | 2017-05-17 |
| CN104321060B (zh) | 2018-08-07 |
| US20140364396A1 (en) | 2014-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201605152SA (en) | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | |
| HK1211569A1 (en) | Amino acid derivatives | |
| IL227594A0 (en) | Substituted aminobutyric compounds as neprilysin inhibitors | |
| HK1195552A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
| EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
| EP2704573A4 (en) | AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES | |
| IL235425B (en) | History of lysine-glutamic acid di-peptide | |
| ZA201401884B (en) | New dihydroquinoline-2-one derivatives | |
| EP2705025A4 (en) | Hydroxymethyl-biaryl BENZOTRIAZOL DERIVATIVES | |
| IL228949A0 (en) | History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors | |
| PL2721039T3 (pl) | Chelatowane inhibitory PSMA | |
| GB201304499D0 (en) | Carcainium Salts | |
| SG11201401937YA (en) | New aryl-quinoline derivatives | |
| HK1199025A1 (en) | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2 | |
| HK1208466A1 (en) | Comt inhibitors comt | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| EP2785766A4 (en) | HYDROXYPOLYAMINSALZE | |
| HK1212997A1 (zh) | 酮酰胺免疫蛋白酶體抑制劑 | |
| EP2744788A4 (en) | Benzopiperazine derivatives as CETP inhibitors | |
| HK1191327A1 (en) | Azaspirodecanone compounds as hsl inhibitors hsl | |
| HK1190706A1 (en) | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes hsl - | |
| ZA201405367B (en) | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| GB201104399D0 (en) | Novel inhibitors |